VERVE-201 Clin0 familial hypercholesterolemia; 3 add'l products RD atherosclerotic cardiovascular disease/liver disease
Verve Therapeutics is developing novel gene editing therapies for the treatment of cardiovascular diseases. The company has a proprietary platform for the development of base editors, which are enzymes that can make precise changes to DNA without causing harmful off-target edits. Base editors are a new class of gene editing tools that have the potential to revolutionize the treatment of genetic diseases. Unlike traditional gene editing tools, such as CRISPR/Cas9, base editors can make precise changes to a single nucleotide in DNA without causing harmful off-target edits. This makes base editors a safer and more effective tool for gene editing. Verve Therapeutics is using its proprietary base editor platform to develop therapies for a variety of cardiovascular diseases, including hypercholesterolemia and sickle cell disease.